Dr. Reddy's Laboratories (RDY) Competitors $14.48 -0.21 (-1.43%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$14.64 +0.16 (+1.10%) As of 07/18/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. TAK, ARGX, ONC, BNTX, INSM, SMMT, TEVA, ITCI, GMAB, and MRNAShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Moderna Takeda Pharmaceutical (NYSE:TAK) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Do institutionals and insiders believe in TAK or RDY? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, TAK or RDY? Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$30.09B1.53$712.33M$0.2265.55Dr. Reddy's Laboratories$3.81B3.17$663M$0.6621.94 Does the media refer more to TAK or RDY? In the previous week, Dr. Reddy's Laboratories had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 5 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.04 beat Dr. Reddy's Laboratories' score of 0.67 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TAK or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.38% compared to Takeda Pharmaceutical's net margin of 2.36%. Dr. Reddy's Laboratories' return on equity of 17.98% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical2.36% 10.64% 5.14% Dr. Reddy's Laboratories 17.38%17.98%12.24% Do analysts rate TAK or RDY? Dr. Reddy's Laboratories has a consensus price target of $16.95, indicating a potential upside of 17.06%. Given Dr. Reddy's Laboratories' higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is TAK or RDY a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.8%. Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend. Which has more risk & volatility, TAK or RDY? Takeda Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. SummaryDr. Reddy's Laboratories beats Takeda Pharmaceutical on 12 of the 18 factors compared between the two stocks. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$12.09B$3.81B$5.54B$20.82BDividend Yield0.56%1.25%3.76%3.65%P/E Ratio21.947.3228.2627.58Price / Sales3.1711.70414.1957.74Price / Cash14.026.2535.8522.27Price / Book3.062.708.114.66Net Income$663M-$109.62M$3.25B$995.72M7 Day Performance-0.21%-3.48%1.63%-0.30%1 Month Performance-4.87%5.98%7.62%4.91%1 Year Performance-7.32%2.83%32.74%11.21% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories2.7649 of 5 stars$14.48-1.4%$16.95+17.1%-7.3%$12.09B$3.81B21.9427,811News CoverageUpcoming EarningsTAKTakeda Pharmaceutical2.0499 of 5 stars$15.04+2.4%N/A+8.0%$47.84B$30.09B68.3447,455Positive NewsHigh Trading VolumeARGXargenex4.477 of 5 stars$561.28+0.2%$728.06+29.7%+19.8%$34.35B$2.25B34.631,599Positive NewsAnalyst RevisionONCBeOne Medicines2.6311 of 5 stars$252.14+0.7%$320.67+27.2%N/A$27.63B$3.81B-67.7811,000Analyst ForecastGap UpBNTXBioNTech1.4617 of 5 stars$111.00-1.7%$137.91+24.2%+28.7%$26.68B$2.98B-32.656,772Analyst ForecastINSMInsmed3.9636 of 5 stars$101.89+3.8%$108.07+6.1%+35.0%$19.33B$381.03M-17.121,271News CoveragePositive NewsAnalyst ForecastInsider TradeSMMTSummit Therapeutics3.0865 of 5 stars$25.40+1.6%$34.67+36.5%+198.2%$18.86BN/A-74.70110TEVATeva Pharmaceutical Industries4.2421 of 5 stars$16.43+0.2%$24.71+50.5%-4.3%$18.84B$16.54B-14.2836,830Analyst DowngradeITCIIntra-Cellular Therapies0.957 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0424 of 5 stars$21.46+0.3%$37.80+76.1%-21.2%$13.77B$3.12B12.192,682Analyst DowngradeAnalyst RevisionMRNAModerna4.2511 of 5 stars$32.87-2.3%$46.61+41.8%-74.2%$12.71B$3.24B-3.775,800Trending NewsOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Takeda Pharmaceutical Alternatives argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Insmed Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Moderna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDY Stock Alerts